Switch theme
Sign up to access all valuation multiples
Yixintang Pharmaceutical Group Co Ltd is a China-based company engages in the operation of pharmaceutical retail chains and wholesale businesses. Its products include traditional Chinese medicine, Western medicine, and medical equipment.
2000
n/a
LTM Revenue $2.6B
LTM EBITDA $213M
$1.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Yixintang Pharmaceutical has a last 12-month revenue of $2.6B and a last 12-month EBITDA of $213M.
In the most recent fiscal year, Yixintang Pharmaceutical achieved revenue of $2.4B and an EBITDA of $275M.
Yixintang Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Yixintang Pharmaceutical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.4B | $2.5B | XXX | XXX | XXX |
| Gross Profit | $743M | $842M | XXX | XXX | XXX |
| Gross Margin | 31% | 34% | XXX | XXX | XXX |
| EBITDA | $275M | $206M | XXX | XXX | XXX |
| EBITDA Margin | 11% | 8% | XXX | XXX | XXX |
| Net Profit | $127M | $139M | XXX | XXX | XXX |
| Net Margin | 5% | 6% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Yixintang Pharmaceutical's stock price is CNY 13 (or $2).
Yixintang Pharmaceutical has current market cap of CNY 7.6B (or $1.0B), and EV of CNY 7.4B (or $1.0B).
See Yixintang Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.0B | $1.0B | XXX | XXX | XXX | XXX | $0.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Yixintang Pharmaceutical has market cap of $1.0B and EV of $1.0B.
Yixintang Pharmaceutical's trades at 0.4x LTM EV/Revenue multiple, and 4.8x LTM EBITDA.
Analysts estimate Yixintang Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Yixintang Pharmaceutical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.0B | XXX | XXX | XXX |
| EV/Revenue | 0.4x | XXX | XXX | XXX |
| EV/EBITDA | 5.0x | XXX | XXX | XXX |
| P/E | 20.5x | XXX | XXX | XXX |
| P/E/Growth | 0.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpYixintang Pharmaceutical's NTM/LTM revenue growth is 10%
Yixintang Pharmaceutical's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Yixintang Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Yixintang Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Yixintang Pharmaceutical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -25% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 19% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 27% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| Oriola | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Yixintang Pharmaceutical acquired XXX companies to date.
Last acquisition by Yixintang Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Yixintang Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Yixintang Pharmaceutical founded? | Yixintang Pharmaceutical was founded in 2000. |
| Where is Yixintang Pharmaceutical headquartered? | Yixintang Pharmaceutical is headquartered in China. |
| Is Yixintang Pharmaceutical publicy listed? | Yes, Yixintang Pharmaceutical is a public company listed on SHE. |
| What is the stock symbol of Yixintang Pharmaceutical? | Yixintang Pharmaceutical trades under 002727 ticker. |
| When did Yixintang Pharmaceutical go public? | Yixintang Pharmaceutical went public in 2014. |
| Who are competitors of Yixintang Pharmaceutical? | Similar companies to Yixintang Pharmaceutical include e.g. MedPlus India, Pague Menos, Droga Raia, Redcare Pharmacy. |
| What is the current market cap of Yixintang Pharmaceutical? | Yixintang Pharmaceutical's current market cap is $1.0B |
| What is the current revenue of Yixintang Pharmaceutical? | Yixintang Pharmaceutical's last 12-month revenue is $2.6B. |
| What is the current EBITDA of Yixintang Pharmaceutical? | Yixintang Pharmaceutical's last 12-month EBITDA is $213M. |
| What is the current EV/Revenue multiple of Yixintang Pharmaceutical? | Current revenue multiple of Yixintang Pharmaceutical is 0.4x. |
| What is the current EV/EBITDA multiple of Yixintang Pharmaceutical? | Current EBITDA multiple of Yixintang Pharmaceutical is 4.8x. |
| What is the current revenue growth of Yixintang Pharmaceutical? | Yixintang Pharmaceutical revenue growth between 2023 and 2024 was 4%. |
| Is Yixintang Pharmaceutical profitable? | Yes, Yixintang Pharmaceutical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
